

**Department of Human Services – Office of Medical Assistance Programs  
Prior Authorization Feedback on Public Input from January 22, 2026**

Drug	Comment	Commenter	Agree	Agree In Part	Disagree	Response
GLP-1 Receptor Agonists	<ul style="list-style-type: none"> <li>Was there an intention to ask for Zepbound before Wegovy tablet also? As currently written, that is not the case.</li> <li>Is it possible to streamline point 2 and 3.e. within the renewal criteria?</li> </ul>	Fallan Vaisberg, PharmD Formulary Pharmacist Jefferson Health Plans		X		<p>Guidelines were revised to address the first comment.</p> <p>Regarding the second comment, PA DHS recognizes that the GLP-1 Receptor Agonists renewal guidelines 2. and 3.e. are very similarly worded, but we view them as two distinct guidelines serving different purposes. Renewal guideline 2. is intended to evaluate requests for currently non-preferred GLP-1 Receptor Agonists that were previously approved (e.g., requests for Wegovy or Zepbound, which were both Preferred prior to 01/01/26) and promote a switch to the most cost effective GLP-1 Receptor Agonist (e.g., Ozempic) whenever possible. Guideline 3.e. is specific to renewal requests when a prescriber is attempting to switch from one GLP-1 Receptor Agonist to another. For example, a beneficiary may have been previously approved for Ozempic for moderate to severe sleep apnea and during evaluation of a renewal request the beneficiary has not met one or more of the renewal guidelines 3.a.iii a), b) or c). but they also no longer meet the initial prior authorization guidelines (e.g., their BMI decreased to just below 35 while on therapy with Ozempic). Renewal guideline 3.e.i. would allow for approval of the switch to the next most cost effective GLP-1 Receptor Agonist (e.g., Wegovy 2.4 mg). In addition, renewal guideline 3.e.ii. serves as a placeholder to evaluate the rationale for a change in therapy from one preferred GLP-1 Receptor Agonist to another if additional GLP-1 Receptor Agonists are added to preferred status in the future.</p>